Commerce Bank Sells 5,400 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Commerce Bank lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 39.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,352 shares of the company’s stock after selling 5,400 shares during the period. Commerce Bank’s holdings in Henry Schein were worth $609,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HSIC. American Century Companies Inc. raised its position in Henry Schein by 3.1% during the 2nd quarter. American Century Companies Inc. now owns 5,484,286 shares of the company’s stock valued at $351,543,000 after purchasing an additional 162,477 shares in the last quarter. Swedbank AB purchased a new position in shares of Henry Schein during the first quarter valued at $215,998,000. Nuance Investments LLC raised its holdings in shares of Henry Schein by 6.2% in the second quarter. Nuance Investments LLC now owns 1,863,333 shares of the company’s stock valued at $119,440,000 after acquiring an additional 108,143 shares in the last quarter. Burgundy Asset Management Ltd. lifted its stake in Henry Schein by 1.0% in the second quarter. Burgundy Asset Management Ltd. now owns 1,640,379 shares of the company’s stock worth $105,148,000 after acquiring an additional 16,476 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Henry Schein by 10.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,634,384 shares of the company’s stock worth $104,764,000 after acquiring an additional 149,517 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 2.3 %

Henry Schein stock opened at $76.84 on Tuesday. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.63. The stock has a market cap of $9.58 billion, a PE ratio of 31.62, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a 50-day moving average of $70.89 and a two-hundred day moving average of $69.73.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. Henry Schein’s revenue was up .4% on a year-over-year basis. During the same period last year, the firm posted $1.32 EPS. On average, research analysts anticipate that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Insider Transactions at Henry Schein

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The trade was a 22.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael S. Ettinger sold 12,240 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the sale, the chief operating officer now owns 87,706 shares in the company, valued at approximately $6,577,950. The trade was a 12.25 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HSIC shares. Robert W. Baird reduced their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. dropped their target price on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. UBS Group reduced their price target on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, Evercore ISI upped their price objective on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.89.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.